Finance

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, in more than five years.

Capital Daily Newsroom

Editorial Desk

2026-06-22 · 2 min read

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push

Published June 22, 2026 · Category: Finance

Overview

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, in more than five years.

Source

Originally published at www.cnbc.com.

Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.